Abstract
I have read “Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis” by Wong and colleagues1 with great interest. In this meta-analysis, the authors included 14 randomized, controlled trials (9012 patients) comparing dual versus mono antiplatelet therapy for acute noncardioembolic ischemic stroke or transient ischemic attack (TIA) within 3 days of ictus. They found that when compared with mono antiplatelet therapy, dual therapy was associated with a reduction in stroke recurrence, and composite vascular events, but without a significant increase in the risk of major bleeding. As the authors state, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
